Erica Weinstein joined Flagship Pioneering in 2015 after completing the firm's Fellowship Program. At Flagship, Erica works as part of a team of entrepreneurial scientists exploring innovative ideas and developing the science, intellectual property, and business strategy that form the foundation of breakthrough startups.
At Flagship, Erica co-founded Ring Therapeutics, Laronde Therapeutics and ProFound Therapeutics and launched Inzen Therapeutics. At Laronde, Erica led the value creation strategy along with the biology team. Previously at Ring, she led the translation team where she invented and developed the company’s Anellovector platform.
Before joining Flagship, Erica earned her doctorate in biomedical sciences at the Icahn School of Medicine at Mount Sinai, where she researched the emerging role of the microbiome in autoimmune disease development. During her studies, Erica was the recipient of the Helmsley Charitable Trust Fellowship and the Levine Foundation Fellowship Awards. Erica received her B.S. in biology and minor in global health, culture, and society from Emory University. Erica's work has resulted in numerous patents and publications. Erica was honored in 2017 as a top female leader in Business Insider's 30 Biotech leaders under 40, and in 2021 in Business Insiders’ list of 12 young serial entrepreneurs building the next generation of biotech startups.